We have observed
6 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 12, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
INSULIN GLARGINE VERSUS METFORMIN FOR THE FIRST-LINE TREATMENT OF EARLY TYPE 2 DIABETES
BASAL INSULIN THERAPY
A novel soluble biomarker for insulin resistance
PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9
TREATMENT OF DIABETES MELLITUS BY LONG ACTING FORMULATIONS OF INSULINS
NEW ADMINISTRATION ROUTES OF INSULIN, INSULIN ANALOGS OR DERIVATIVES OF INSULIN